A Lifestyle Intervention to Improve in Vitro Fertilization Results

Lifestyle Clinical Trial

— W+D  

Official title:

A Lifestyle Intervention to Improve in Vitro Fertilization Results

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02648555
• Other study ID #: Protocol W+D
• Status: Not yet recruiting
• Phase: N/A
• First received: January 4, 2016
• Last updated: January 6, 2016
• Start date: May 2016
• Est. completion date: May 2018

Study information

• Verified date: January 2016
• Source: Hospital dos Servidores do Estado do Rio de Janeiro
• Contact: Silvia Hoirisch-Clapauch, MD, PhD
• Phone: +55-21-999737500
• Email: sclapauch[@]ig.com.br
• Is FDA regulated: No
• Health authority: Brazil: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Embryo adhesion and placentation depend on tissue plasminogen activator (tPA)-mediated activation of brain-derived neurotrophic factor, vascular endothelial growth factor and other growth factors, formation of hemidesmosomes, and degradation of extracellular matrix and basement membrane, either directly or by activating matrix metalloproteinases.

Since glucose and insulin stimulate release of a major tPA inhibitor by endothelial cells - plasminogen activator inhibitor (PAI)-1 - the investigators hypothesized that lifestyle interventions proven effective in maintaining glucose and insulin levels within the normal range would increase the take home baby rate in women undergoing assisted reproduction.

Description:

Tissue plasminogen activator (tPA) has a well-known role in the coagulation pathway. tPA converts plasminogen to plasmin. Plasmin dissolves fibrin clots, thus limiting thrombus formation to the site of vascular injury.

In the extravascular compartment, tPA is a pivotal mediator of tissue formation and remodeling. Due to its proteolytic activity, tPA participates in processes as diverse as embryo adhesion, placental angiogenesis and vasculogenesis, and neuronal plasticity. Embryo adhesion and placentation, for example, depend on tPA-mediated activation of brain-derived neurotrophic factor, vascular endothelial growth factor and other growth factors, formation of hemidesmosomes, and degradation of extracellular matrix and basement membrane, either directly or by activating matrix metalloproteinases.

Assuming low tPA activity would impair both blood clot dissolution and placentation, the investigators postulated that patients with consecutive first-trimester abortions would have a high prevalence of severe dysmenorrhea, accompanied by the passage of large clots.

In 2011, the investigators assessed the prevalence of severe dysmenorrhea during early adolescence in two groups. The first one was made of women with ≥ 2 consecutive first-trimester abortions, and the other, of women with ≥ 2 living births, and no losses or preterm deliveries. Severe dysmenorrhea was defined as suprapubic menstrual cramp, intense enough to cause repeated absenteeism from school or fainting in the absence of analgesia. Early adolescents are unlikely to use contraceptives, or to have become pregnant, two situations that may reduce the pain. In this study, severe dysmenorrhea increased the chances of having consecutive first-trimester miscarriages by sevenfold (95% Confidence Interval: 3.4 to 14.1; p<0.001).

Since glucose and insulin stimulate release of a major tPA inhibitor by endothelial cells - plasminogen activator inhibitor (PAI)-1 - the investigators hypothesized that lifestyle interventions proven effective in maintaining glucose and insulin levels within the normal range would increase the take home baby rate in women undergoing assisted reproduction.

The protocol has already been tested at a Brazilian tertiary care center in women with unexplained consecutive first-trimester abortions, conceiving spontaneously. The objective of this study was to observe the impact of lifestyle interventions on the take home baby rate, and to observe if the intervention could reduce the prevalence of preeclampsia and neonatal hypoglycemia.

From 2011 to 2015, 480 patients aged 18 to 42 years with ≥ 2 consecutive first-trimester abortions documented by pathology or ultrasonography, were randomly assigned to protocol Walking and Diet (W+D) or to standard follow-up (controls). Women were enrolled independent of having had severe dysmenorrhea during adolescence. Patients assigned to protocol W+D were instructed to walk briskly for ≥ 40 minutes seven days a week. In addition, they were recommended to avoid high-carbohydrate meals such as snacks, candies, fiber-free juices, coconut water and sugar-sweetened beverages, and to eat two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting when they decided to get pregnant and continuing until delivery. Women with antiphospholipid antibodies, second- or third-trimester losses, multiple pregnancies, anatomical abnormalities that could increase the risk of first-trimester abortions, or any condition requiring a priori anticoagulation were excluded.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 240
• Est. completion date: May 2018
• Est. primary completion date: May 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• women undergoing assisted reproduction

Exclusion Criteria:

1. liver failure, kidney failure or other conditions that prevent the patient from eating proteins.

2. multiple pregnancy.

3. paraplegia, hemiplegia, arthropathy and other conditions that prevent the participant from exercising.

4. participants lost to follow-up.

5. conditions that may strongly affect pregnancy results, such as a serious accident

6. participants assigned to non-intervention group following the recommendations given to intervention group.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Hypoglycemia
• Lifestyle
• Neonatal Hypoglycemia
• Placenta; Implantation
• Risk Reduction Behavior
• Sterility

Intervention

Behavioral:
• Daily walking
Participants will be instructed to walk briskly for >40 minutes, 7 days a week.
• Dietary recommendations
Participants will be instructed to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting at least one week before embryo transfer and continuing until delivery. They will be also recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber), such as snacks, candies, fiber-free juices, coconut water, and sugar-sweetened beverages, particularly carbonated soft drinks and sport drinks. Patients suffering from nausea usually do not tolerate solid food. As a result, fiber-free juices and sugar-sweetened beverages account of most of their caloric intake, which may cause non-adherence to the protocol. Women with nausea or vomiting will be treated with ondansetron.

Locations

Country	Name	City	State
Brazil	Hospital Federal dos Servidores do Estado, Ministry of Health	Rio de Janeiro	RJ

Sponsors (2)

Lead Sponsor	Collaborator
Hospital dos Servidores do Estado do Rio de Janeiro	Hospital Universitário Gaffrée Guinle

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The rate of viable pregnancies		two years	No
Secondary	The rate of fist trimester losses		four years	No
Secondary	The rate of second and third trimester losses		four years	No
Secondary	The rate of preeclampsia, eclampsia and HELLP syndrome		four years	No
Secondary	Cramps or bleeding during the first trimester requiring progesterone		four years	No
Secondary	The rate of prematurity		four years	No
Secondary	The rate of intrauterine growth restriction		four years	No
Secondary	Maternal weight gain		four years	No
Secondary	The rate of gestational diabetes		four years	No
Secondary	The rate of neonatal hypoglycemia		four years	No
Secondary	The rate of neonatal hyperbilirubinemia requiring phototherapy		four years	No